AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06553417 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urea 10%
Description: Intervention 2: Urea 10%~* This intervention involves the use of a 10% urea-based topical moisturizing product.~* Subjects in Group B will be instructed to apply the 10% urea moisturizer twice daily to the upper and lower limbs, including both lesional and non-lesional areas of the skin.~The use of these interventions will be evaluated over a 12-week period, with assessments of Transepidermal Water Loss (TEWL), skin hydration, skin pH, index scoring of atopic dermatitis (SCORAD), erythema area severity index (EASI), pruritus visual analogue scale (PVAS), quality of life (DLQI), and any adverse effects.
Study NCT05772871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaiqihuang granule
Description: Huaiqihuang Granule, oral administration, recommended daily dose: for body weight \<10 kg, 5g, twice a day; for 10 kg ≤ body weight \<20 kg, 10g, twice a day; for 20 kg≤body weight \<30 kg, 15g, twice a day; for 30 kg≤body weight \<50 kg, 20g, twice a day; for body weight>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
Study NCT05772871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone, oral administration, recommended dose: 2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks. If patients have relapsed during reducing dosage or withdrawal, the patients will receive Prednisone for 8 weeks again \[2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks\]. If a second relapse is observed, patients will receive immunosuppressants and then withdraw from the trial.
Study NCT05772871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone, oral administration, recommended dose: 2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks. If patients have relapsed during reducing dosage or withdrawal, the patients will receive Prednisone for 8 weeks again \[2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks\]. If a second relapse is observed, patients will receive immunosuppressants and then withdraw from the trial.
Study NCT05662137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotions Recognition and Expression
Description: Emotion recognition and expression program consisting of 8 sessions will be used. In this program, patients will have the opportunity to describe their emotions, explain emotions that are difficult to express such as anger, sadness, shame, guilt, and discuss the consequences of suppressed emotions.
Study NCT05826951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol (0.8g/kg)
Study NCT05826951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT05826951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05772871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamisole placebo
Description: Levamisole placebo, 1.25 mg/kg. once daily. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
Study NCT05772871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levamisole
Description: Levamisole, 1.25 mg/kg. once daily. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
Study NCT05772871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Huaiqihuang Granule placebo
Description: Huaiqihuang Granule placebo, oral administration, recommended daily dose: for body weight \<10 kg, 5g, twice a day; for 10 kg ≤ body weight \<20 kg, 10g, twice a day; for 20 kg≤body weight \<30 kg, 15g, twice a day; for 30 kg≤body weight \<50 kg, 20g, twice a day; for body weight>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
Study NCT04978571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous electrical nerve-field stimulation, PENFS
Description: A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
Study NCT04978571 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: percutaneous electrical nerve-field stimulation, PENFS (sham device)
Description: A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear. The sham device will not deliver field stimulation to the ear.
Study NCT04978571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous electrical nerve-field stimulation, PENFS (COVID active device)
Description: A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
Study NCT05387837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-4517.2
Description: D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)
Study NCT05691920 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pectointercostal plane block and external oblique intercostal plane block
Description: Patients will be subjected to bilateral external oblique intercostal plane and pectointercostal plane blocks
Study NCT05691920 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl infusion
Description: Patients will be subjected to fentanyl infusion at a rate of 1μg/kg/h
Study NCT05404893 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal calprotectin measurement
Description: Stool samples will be collected and fecal calprotectin levels will be measured using an enzymatic immunoassay kit.
Study NCT05824442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample for multiplex QPCR technique
Description: Blood sampling specifically for qPCR Echino at inclusion and one year after
Study NCT06530264 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DCR
Description: 6. An H shaped incision at the postero-inferior lacrimal sac is made, with a long anterior flap and shorter posterior flap. Similarly an H shaped incision at the nasal mucosa is made. The posterior flap of lacrimal sac is sutured with posterior flap of nasal mucosa in interrupted fashion using 6-0 vicryl sutures in Group A, while in Group B the posterior flap is trimmed without suturing.
Study NCT06554548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10518
Description: Treatment A: Single oral dose of HS-10518 160 mg tablet under fasted conditions Treatment B: Single oral dose of HS-10518 160 mg tablet after a high-fat meal
Study NCT05214287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypoxic Gas Mixture
Description: Using a commercially available hypoxicator, varying gas mixtures as described will be administered via a tight-fitting oxygen mask. In the circuitry, a three-way valve is placed that allows for the intermittent administration of hypoxia: the valve either passes the hypoxic mixture from the hypoxicator or room air.
Study NCT05214287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hypoxic Gas Mixture
Description: Using a commercially available hypoxicator, varying gas mixtures as described will be administered via a tight-fitting oxygen mask. In the circuitry, a three-way valve is placed that allows for the intermittent administration of hypoxia: the valve either passes the hypoxic mixture from the hypoxicator or room air.
Study NCT03680976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-10
Description: Liquid-filled capsule containing 150 mg CXA-10 in super refined olive oil.
Study NCT03680976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid-filled capsule containing olive oil manufactured to mimic CXA-10 150 mg capsule
Study NCT04703517 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Point of care ultrasound
Description: Patients will receive a point of care ultrasound at the bedside in the Emergency Department and compare the impression to the x ray result
Study NCT06580327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: programmed intermittent Bolus epidural analgesia
Description: About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the study group protocol for pain maintenance, i.e., a programmed intermittent bolus of 10 ml of 0.1% bupivacaine and 2 μg/ml fentanyl every hour until the completion of labor and suturing of the incision. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score >30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study.
Study NCT06580327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuous epidural infusion
Description: About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the control group protocol for pain maintenance, i.e., 0.1% Bupivacaine and 2 μg/ml fentanyl as a continuous infusion per one hour, until the delivery is completed, and laceration is sutured. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score >30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study.
Study NCT06608940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC3402
Description: BC3402, intravenous, 20 mg/kg, D1 and D15 of every 28 day cycle, continuous. BC3402 to be administered after completion of the infusion of durvalumab and/or tremelimumab on the days when BC3402 is to be administered with durvalumab and/or tremelimumab
Study NCT06608940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab, intravenous, 1500 mg, every 4 weeks, continuous
Study NCT06608940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab, intravenous, 300 mg, 1 dose on Cycle 1 Day 1
Study NCT06617377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scan
Description: advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scan (estimated total scanning time = 45 min for all centers except for Toulouse = 60min) will be acquired at least after 72h from complete withdrawal of sedation in normothermia condition (between Day 1 and Day 7 after inclusion).
Study NCT06680817 — intervention group
Intervention type: DRUG
Intervention: Faricimab
Description: Faricimab will be administered as per local clinical practice and local labeling.
Study NCT06616974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TX000045- Dose A
Description: The participants will receive a subcutaneous injection of Dose A of TX000045 every 2 weeks for 24 weeks.
Study NCT06616974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TX000045- Dose B
Description: The participants will receive subcutaneous injection of Dose B of TX000045 every 4 weeks for 24 weeks where they will alternate between TX000045 and placebo every 2 weeks.
Study NCT06616974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will receive a subcutaneous injection of placebo every 2 weeks for 24 weeks.
Study NCT06616116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biosignal feedback
Description: 1. Real-time neurofeedback guided mindfulness~   : Unlike standard mindfulness therapies, this intervention integrates real-time monitoring of brainwave activity (EEG). Participants in the experimental group receive immediate auditory feedback during their mindfulness sessions, which helps guide their practice and enhance engagement.~2. Tailored progress report In addition to real-time feedback, participants in the Mindfulness with biosignal feedback group receive detailed reports of their biosignal data (EEG and HRV) before, during, and after each session. These reports allow for deeper self-reflection and personalized adjustments to their mindfulness practice, which is not commonly provided in other mindfulness programs.
Study NCT06616116 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Biosignal Monitoring (EEG and HRV) during Mindfulness without real-time feedback
Study NCT04751474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational messages
Description: Participants in the motivational group were sent to motivational messages to their mobile phones for 21 days.
Study NCT06083636 — intervention group
Intervention type: OTHER
Intervention: Single extra blood draw and completion of single questionnaire
Description: Single blood draw of 3 tubes (20 mL) additional to regular blood draw will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.
Study NCT06083636 — intervention group
Intervention type: OTHER
Intervention: Single blood draw and completion of single questionnaire
Description: Single blood draw of 3 tubes (20 mL) will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.
Study NCT05629871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: Polysomnography will be performed for 24 hours at inclusion and 24 months
Study NCT05005065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C005 X mg
Description: Oral capsule
Study NCT05005065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A001 Y mg
Description: Oral tablet
Study NCT05005065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C005 Y mg
Description: Oral capsule
Study NCT05005065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C005 Z mg
Description: Oral capsule
Study NCT05629871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment
Description: A full neuropsychological assessment will be performed at inclusion, 12 and 24 months
Study NCT05629871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires on sleep and behavioural problems
Description: Questionnaires on sleep and behavioural problems
Study NCT05629871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Actimetry
Description: Measurement of actimetrics for 14 days at inclusion and at 24 months
Study NCT05629871 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fractional diuresis
Description: Split diuresis from 7pm-7am, 7am-12am and 12pm-19pm during polysomnography at inclusion inclusion and 24 months to measure melatonin concentration
Study NCT05629871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal temperature measurement
Description: eCelsius capsule to measure internal temperature at inclusion and 24 months
Study NCT05629871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker assay
Description: Determination of the biomarkers Aβ42, Aβ40, Tau and P-Tau in blood and in the cerebrospinal fluid
Study NCT03271515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 anti-CD20 Bispecific CAR-T
Description: patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.
Study NCT06660355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is a Janus kinase inhibitor.
Study NCT06660355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone is a glucocorticoid.
Study NCT06661304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benson Relaxation Exercise
Description: Benson relaxation exercise is based on the patient relaxing their body muscles by focusing on deep breathing and a word that means something to them.
Study NCT06661304 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ongoing treatment
Description: In addition to their medical treatment and care in the clinics, patients participate in activities such as group activities, leisure time and walking.
Study NCT05197855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deem 3 Headband
Description: The patient will wear the Dreem 3 headband and pulse oximeter at home before initiation of CPAP (for 7 nights) and during a month of treatment (for a minimum of 9 nights), after the initiation of CPAP. He will also wear a glucose sensor and a pedometer during the entire study period before and after CPAP treatment.
Study NCT05852327 — intervention group
Intervention type: OTHER
Intervention: Observation only
Description: Observation only
Study NCT06513234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib and obinutuzumab
Description: Orelabrutinib and obinutuzumab 6cycles ;orelabrutinib 150mg
Study NCT06231277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH002
Description: Every 21 days constitutes a treatment cycle, and administration begins on the first day of each cycle
Study NCT06631040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti CD19 CAR NK cells
Description: Ten eligible patients with relapsed Acute Lymphoblastic Leukemia will be enrolled based on inclusion criteria and informed consent. After conditioning with Fludarabine and Cyclophosphamide, patients will receive a single infusion of anti-CD19 CAR NK cells with close monitoring using one of the following dose levels: • Dose Level 1: 1×10\^7/Kg • Dose Level 2: 5×10\^7/Kg • Dose Level 3: 1×10\^8/Kg Safety Assessment: Adverse events will be recorded and graded. Laboratory parameters and cytokine release syndrome (CRS) markers will be closely monitored. Efficacy Evaluation: Response assessments will follow International Lymphoma Party (LWP) Group guidelines, including complete response (CR), partial response (PR), stable disease (SD), and progressive disease.
Study NCT03137966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine
Description: Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
Study NCT03137966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
Study NCT06196944 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Augmentative Alternative Communication
Description: Traditional Method
Study NCT06687785 — intervention group
Intervention type: PROCEDURE
Intervention: Entire Papilla Preservation Technique
Description: A buccal intrasulcular incision was made in the tooth with the defect and a vertical incision was made extending from the buccal center of the tooth to the mesial papillary crest and crossing the mucogingival line. Then, using a micro periosteal elevator, a full-thickness mucoperiosteal flap was lifted from the incision site to the defect under the papilla. After removal of the granulation tissues in the area, bone graft was applied for regenerative purposes and the vertical incision was sutured with 6/0 polypropylene suture using simple suture technique.
Study NCT06687785 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional Flap Surgery Technique
Description: After buccal and lingual intrasulcular incisions were made to eliminate the teeth and papillae adjacent to the defect, a full-thickness mucoperiosteal flap was raised in the vestibular and lingual direction with a periosteal elevator. After removal of the granulation tissues in the area, bone graft was applied for regenerative purposes and the papillary incisions were sutured with 5/0 polypropylene suture using simple suture technique.
Study NCT06720298 — intervention group
Intervention type: DRUG
Intervention: 18F-FDG
Description: All study participants will undergo one 18F-FDG PET/ CT scan.
Study NCT05028712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Information Training
Description: Participants in this arm will receive training to improve the use of residual vision to enhance functional performance.
Study NCT05028712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal training
Description: Participants in this arm will receive training in integrating input from different senses to enhance functional performance.
Study NCT04783610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Ethanol will be administered via oral route.